Cargando…
Skipping the co-expression problem: the new 2A "CHYSEL" technology
The rapid progress in the field of genomics is increasing our knowledge of multi-gene diseases. However, any realistic hope of gene therapy treatment for those diseases needs first to address the problem of co-ordinately co-expressing several transgenes. Currently, the use of internal ribosomal entr...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC521497/ https://www.ncbi.nlm.nih.gov/pubmed/15363111 http://dx.doi.org/10.1186/1479-0556-2-13 |
_version_ | 1782121841090887680 |
---|---|
author | de Felipe, Pablo |
author_facet | de Felipe, Pablo |
author_sort | de Felipe, Pablo |
collection | PubMed |
description | The rapid progress in the field of genomics is increasing our knowledge of multi-gene diseases. However, any realistic hope of gene therapy treatment for those diseases needs first to address the problem of co-ordinately co-expressing several transgenes. Currently, the use of internal ribosomal entry sites (IRESs) is the strategy chosen by many researchers to ensure co-expression. The large sizes of the IRESs (~0.5 kb), and the difficulties of ensuring a well-balanced co-expression, have prompted several researchers to imitate a co-expression strategy used by many viruses: to express several proteins as a polyprotein. A small peptide of 18 amino acids (2A) from the foot-and-mouth disease virus (FMDV) is being used to avoid the need of proteinases to process the polyprotein. FMDV 2A is introduced as a linker between two proteins to allow autonomous intra-ribosomal self-processing of polyproteins. Recent reports have shown that this sequence is compatible with different sub-cellular targeting signals and can be used to co-express up to four proteins from a single retroviral vector. This short peptide provides a tool to allow the co-expression of multiple proteins from a single vector, a useful technology for those working with heteromultimeric proteins, biochemical pathways or combined/synergistic phenomena. |
format | Text |
id | pubmed-521497 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-5214972004-10-07 Skipping the co-expression problem: the new 2A "CHYSEL" technology de Felipe, Pablo Genet Vaccines Ther Commentary The rapid progress in the field of genomics is increasing our knowledge of multi-gene diseases. However, any realistic hope of gene therapy treatment for those diseases needs first to address the problem of co-ordinately co-expressing several transgenes. Currently, the use of internal ribosomal entry sites (IRESs) is the strategy chosen by many researchers to ensure co-expression. The large sizes of the IRESs (~0.5 kb), and the difficulties of ensuring a well-balanced co-expression, have prompted several researchers to imitate a co-expression strategy used by many viruses: to express several proteins as a polyprotein. A small peptide of 18 amino acids (2A) from the foot-and-mouth disease virus (FMDV) is being used to avoid the need of proteinases to process the polyprotein. FMDV 2A is introduced as a linker between two proteins to allow autonomous intra-ribosomal self-processing of polyproteins. Recent reports have shown that this sequence is compatible with different sub-cellular targeting signals and can be used to co-express up to four proteins from a single retroviral vector. This short peptide provides a tool to allow the co-expression of multiple proteins from a single vector, a useful technology for those working with heteromultimeric proteins, biochemical pathways or combined/synergistic phenomena. BioMed Central 2004-09-13 /pmc/articles/PMC521497/ /pubmed/15363111 http://dx.doi.org/10.1186/1479-0556-2-13 Text en Copyright © 2004 de Felipe; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open-access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Commentary de Felipe, Pablo Skipping the co-expression problem: the new 2A "CHYSEL" technology |
title | Skipping the co-expression problem: the new 2A "CHYSEL" technology |
title_full | Skipping the co-expression problem: the new 2A "CHYSEL" technology |
title_fullStr | Skipping the co-expression problem: the new 2A "CHYSEL" technology |
title_full_unstemmed | Skipping the co-expression problem: the new 2A "CHYSEL" technology |
title_short | Skipping the co-expression problem: the new 2A "CHYSEL" technology |
title_sort | skipping the co-expression problem: the new 2a "chysel" technology |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC521497/ https://www.ncbi.nlm.nih.gov/pubmed/15363111 http://dx.doi.org/10.1186/1479-0556-2-13 |
work_keys_str_mv | AT defelipepablo skippingthecoexpressionproblemthenew2achyseltechnology |